BRIEF-Briacell, Briapro Enter Into Asset Purchase Agreement For Exclusive Soluble CD80 License

Reuters

Feb 19

Feb 18 (Reuters) - Briacell Therapeutics Corp BCT.TO:

BRIACELL AND BRIAPRO ENTER INTO ASSET PURCHASE AGREEMENT FOR EXCLUSIVE SOLUBLE CD80 LICENSE
BRIACELL THERAPEUTICS CORP - BRIAPRO GAINS WORLDWIDE RIGHTS TO DEVELOP AND COMMERCIALIZE SCD80
BRIACELL THERAPEUTICS CORP - BRIAPRO TO PAY 2% ROYALTIES TO UMBC UPON COMMERCIALIZATION
BRIACELL THERAPEUTICS CORP - TO PROVIDE BRIAPRO UP TO $3 MILLION FOR RESEARCH AND DEVELOPMENT
BRIACELL THERAPEUTICS CORP: AS PART OF TRANSACTION, BRIACELL WILL MAKE AVAILABLE TO BRIAPRO UP TO $3 MILLION TO FUND RESEARCH AND DEVELOPMENT EFFORT

Source text: ID:nGNX7vF2SN

Further company coverage: BCT.TO

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2612420559"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2612420559\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2612420559?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-19 07:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612420559","market":"nz","top_or_hot":-1,"title":"BRIEF-Briacell, Briapro Enter Into Asset Purchase Agreement For Exclusive Soluble CD80 License","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Briacell, Briapro Enter Into Asset Purchase Agreement For Exclusive Soluble CD80 License</title></head><body><p><span>Feb 18 (Reuters)</span><span> - </span>Briacell <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Corp <span>BCT.TO</span>:</p><ul><li><p>BRIACELL AND BRIAPRO ENTER INTO ASSET PURCHASE AGREEMENT FOR EXCLUSIVE SOLUBLE CD80 LICENSE</p></li><li><p>BRIACELL THERAPEUTICS CORP - BRIAPRO GAINS WORLDWIDE RIGHTS TO DEVELOP AND COMMERCIALIZE SCD80</p></li><li><p>BRIACELL THERAPEUTICS CORP - BRIAPRO TO PAY 2% ROYALTIES TO UMBC UPON COMMERCIALIZATION</p></li><li><p>BRIACELL THERAPEUTICS CORP - TO PROVIDE BRIAPRO UP TO $3 MILLION FOR RESEARCH AND DEVELOPMENT</p></li><li><p>BRIACELL THERAPEUTICS CORP: AS PART OF TRANSACTION, BRIACELL WILL MAKE AVAILABLE TO BRIAPRO UP TO $3 MILLION TO FUND RESEARCH AND DEVELOPMENT EFFORT</p></li></ul><p>Source text: <span>ID:nGNX7vF2SN</span></p><p>Further company coverage: <span>BCT.TO</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Briacell, Briapro Enter Into Asset Purchase Agreement For Exclusive Soluble CD80 License</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Briacell, Briapro Enter Into Asset Purchase Agreement For Exclusive Soluble CD80 License\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-19 07:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Briacell, Briapro Enter Into Asset Purchase Agreement For Exclusive Soluble CD80 License</title></head><body><p><span>Feb 18 (Reuters)</span><span> - </span>Briacell <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Corp <span>BCT.TO</span>:</p><ul><li><p>BRIACELL AND BRIAPRO ENTER INTO ASSET PURCHASE AGREEMENT FOR EXCLUSIVE SOLUBLE CD80 LICENSE</p></li><li><p>BRIACELL THERAPEUTICS CORP - BRIAPRO GAINS WORLDWIDE RIGHTS TO DEVELOP AND COMMERCIALIZE SCD80</p></li><li><p>BRIACELL THERAPEUTICS CORP - BRIAPRO TO PAY 2% ROYALTIES TO UMBC UPON COMMERCIALIZATION</p></li><li><p>BRIACELL THERAPEUTICS CORP - TO PROVIDE BRIAPRO UP TO $3 MILLION FOR RESEARCH AND DEVELOPMENT</p></li><li><p>BRIACELL THERAPEUTICS CORP: AS PART OF TRANSACTION, BRIACELL WILL MAKE AVAILABLE TO BRIAPRO UP TO $3 MILLION TO FUND RESEARCH AND DEVELOPMENT EFFORT</p></li></ul><p>Source text: <span>ID:nGNX7vF2SN</span></p><p>Further company coverage: <span>BCT.TO</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BCTXW","symbol_name":"BriaCell Therapeutics Corp. Warrant","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nTUA3Y80MQ:1","article_id":"2612420559","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2612420559","pubTimestamp":1771456715,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Briacell, Briapro Enter Into Asset Purchase Agreement For Exclusive Soluble CD80 LicenseFeb 18 (Reuters) - Briacell Therapeutics Corp BCT.TO:BRIACELL AND BRIAPRO ENTER INTO ASSET PURCHASE AGREEM","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BCTXW":"BriaCell Therapeutics Corp. Warrant","BCTXL":"BRIACELL THERAPEUTICS CORP C/WTS (TO PUR COM) 15/01/2031","BCTXZ":"BRIACELL THERAPEUTICS CORP C/WTS (TO PUR COM)"},"translate_title":"简介-Briacell与Briapro就可溶性CD80独家许可签订资产购买协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BCTXW":0.9,"BCTXL":0.9,"BCTXZ":0.9},"content_text":"BRIEF-Briacell, Briapro Enter Into Asset Purchase Agreement For Exclusive Soluble CD80 LicenseFeb 18 (Reuters) - Briacell Therapeutics Corp BCT.TO:BRIACELL AND BRIAPRO ENTER INTO ASSET PURCHASE AGREEMENT FOR EXCLUSIVE SOLUBLE CD80 LICENSEBRIACELL THERAPEUTICS CORP - BRIAPRO GAINS WORLDWIDE RIGHTS TO DEVELOP AND COMMERCIALIZE SCD80BRIACELL THERAPEUTICS CORP - BRIAPRO TO PAY 2% ROYALTIES TO UMBC UPON COMMERCIALIZATIONBRIACELL THERAPEUTICS CORP - TO PROVIDE BRIAPRO UP TO $3 MILLION FOR RESEARCH AND DEVELOPMENTBRIACELL THERAPEUTICS CORP: AS PART OF TRANSACTION, BRIACELL WILL MAKE AVAILABLE TO BRIAPRO UP TO $3 MILLION TO FUND RESEARCH AND DEVELOPMENT EFFORTSource text: ID:nGNX7vF2SNFurther company coverage: BCT.TO ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}